KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Capital Expenditures: 2019-2025

Historic Capital Expenditures for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $961.9 million.

  • Royalty Pharma's Capital Expenditures fell 19.48% to $961.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 51.50%. This contributed to the annual value of $2.5 billion for FY2024, which is 18.44% up from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Capital Expenditures is $961.9 million, which was up 86,244.08% from $1.1 million recorded in Q2 2025.
  • Royalty Pharma's Capital Expenditures' 5-year high stood at $1.3 billion during Q3 2021, with a 5-year trough of $85,000 in Q1 2022.
  • For the 3-year period, Royalty Pharma's Capital Expenditures averaged around $507.8 million, with its median value being $496.4 million (2024).
  • Per our database at Business Quant, Royalty Pharma's Capital Expenditures tumbled by 99.98% in 2022 and then skyrocketed by 707,788.24% in 2023.
  • Quarterly analysis of 5 years shows Royalty Pharma's Capital Expenditures stood at $171.7 million in 2021, then soared by 45.71% to $250.2 million in 2022, then spiked by 300.51% to $1.0 billion in 2023, then slumped by 50.47% to $496.4 million in 2024, then fell by 19.48% to $961.9 million in 2025.
  • Its Capital Expenditures was $961.9 million in Q3 2025, compared to $1.1 million in Q2 2025 and $1.1 million in Q1 2025.